The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

AG-K-93813     ethylN-(3-morpholin-4-yl-1- oxa-2-aza-3...

Synonyms: SureCN7804448, BSPBio_002968, KBioGR_001295, KBioSS_000756, M2901_SIGMA, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of molsidomine


Psychiatry related information on molsidomine


High impact information on molsidomine


Chemical compound and disease context of molsidomine


Biological context of molsidomine


Anatomical context of molsidomine


Associations of molsidomine with other chemical compounds


Gene context of molsidomine

  • This study compares the effects of a dose of 1 nmol/kg ET-1 alone on myocardial contractility and myocardial energy metabolism with the effects of 1 nmol/kg ET-1 after pretreatment with 5 mg/kg molsidomine or with 100 microg/kg of the ETA receptor antagonist BQ 610 [24].
  • Poorly controlled diabetic animals were randomized to one of three treatment groups (n = 6 each group); a) untreated, b) HO-1 inhibitor SnPP-IX (50 micromol/kgIP/day), c) NO donor molsidomine (120 mg/L PO/day) and were compared with age and sex matched non diabetic control animals with or without SnPP-IX treatment [25].
  • Both SnPP-IX and molsidomine treatments prevented a diabetes increase of RI, in spite of increased ET-1 expression and were associated with increased iNOS mRNA [25].
  • Administration of molsidomine 30 minutes before or 1, 2, and 3 hours after Con A injection significantly reduced serum ALT levels and attenuated hepatocyte apoptosis from caspase inactivation [26].
  • Molsidomine prevented an I-R-induced increase in superoxide anion and reduced plasma levels of pro-inflammatory cytokines (TNF-alpha, IL-1beta and IFN-gamma), whereas it enhanced anti-inflammatory cytokines (IL-6 and IL-10) [27].

Analytical, diagnostic and therapeutic context of molsidomine

  • Mice treated with molsidomine had enhanced liver proteasome activity 6 hours after treatment, but after 24 hours enzyme activity declined below control levels [28].
  • This study investigated the effects of linsidomine, the active metabolite of molsidomine, on systemic and splanchnic hemodynamics in rats with CCl4-induced cirrhosis using the microsphere technique [2].
  • An assessment of single doses of 8 mg sustained-release molsidomine using serial exercise tests [21].
  • One hour after administration of molsidomine, the appearance of signs of ischaemia in the ECG were considerably delayed and they were reduced in magnitude [21].
  • One hundred percent survival was achieved in the group of animals treated with the NO donor, whereas the groups of animals undergoing I-R that did not receive molsidomine showed a 40% mortality from the second day after reperfusion [29].


  1. Molsidomine in the treatment of patients with angina pectoris. Majid, P.A., DeFeyter, P.J., Van der Wall, E.E., Wardeh, R., Roos, J.P. N. Engl. J. Med. (1980) [Pubmed]
  2. Systemic and splanchnic hemodynamic effects of molsidomine in rats with carbon tetrachloride-induced cirrhosis. Desmorat, H., Vinel, J.P., Lahlou, O., Pipy, B., Badia, P., Cales, P., Combis, J.M., Souqual, M.C., Pascal, J.P. Hepatology (1991) [Pubmed]
  3. Hemodynamic evaluation of molsidomine: a vasodilator with antianginal properties in patients with alcoholic cirrhosis. Vinel, J.P., Monnin, J.L., Combis, J.M., Calés, P., Desmorat, H., Pascal, J.P. Hepatology (1990) [Pubmed]
  4. Hypercholesterolemia in rats induces podocyte stress and decreases renal cortical nitric oxide synthesis via an angiotensin II type 1 receptor-sensitive mechanism. Attia, D.M., Feron, O., Goldschmeding, R., Radermakers, L.H., Vaziri, N.D., Boer, P., Balligand, J.L., Koomans, H.A., Joles, J.A. J. Am. Soc. Nephrol. (2004) [Pubmed]
  5. The nitric oxide donor molsidomine antagonizes age-related memory deficits in the rat. Pitsikas, N., Rigamonti, A.E., Cella, S.G., Sakellaridis, N., Muller, E.E. Neurobiol. Aging (2005) [Pubmed]
  6. Effects of molsidomine on scopolamine-induced amnesia and hypermotility in the rat. Pitsikas, N., Rigamonti, A.E., Cella, S.G., Locatelli, V., Sala, M., Muller, E.E. Eur. J. Pharmacol. (2001) [Pubmed]
  7. Effect of nitric oxide on shock-induced hepatic heme oxygenase-1 expression in the rat. Hoetzel, A., Vagts, D.A., Loop, T., Humar, M., Bauer, M., Pahl, H.L., Geiger, K.K., Pannen, B.H. Hepatology (2001) [Pubmed]
  8. Prophylactic administration of L-arginine improves the intestinal barrier function after mesenteric ischaemia. Schleiffer, R., Raul, F. Gut (1996) [Pubmed]
  9. Effects of molsidomine, a long acting venous dilator, on portal hypertension. A hemodynamic study in patients with cirrhosis. Ruiz del Arbol, L., García-Pagán, J.C., Feu, F., Pizcueta, M.P., Bosch, J., Rodés, J. J. Hepatol. (1991) [Pubmed]
  10. Long-term treatment with the NO-donor molsidomine reduces circulating ICAM-1 levels in patients with stable angina. Van Hove, C., Carreer-Bruhwyler, F., Géczy, J., Herman, A.G. Atherosclerosis (2005) [Pubmed]
  11. Comparison of the hemodynamic responses to molsidomine and isosorbide dinitrate in congestive heart failure. Unger, P., Vachiery, J.L., de Cannière, D., Staroukine, M., Berkenboom, G. Am. Heart J. (1994) [Pubmed]
  12. Prostaglandin I2 and the nitric oxide donor molsidomine have synergistic effects on thromboresistance in man. Sinzinger, H., Rauscha, F., O'Grady, J., Fitscha, P. British journal of clinical pharmacology. (1992) [Pubmed]
  13. Hemodynamic effects of molsidomine, isosorbide dinitrate, and nifedipine at rest and during exercise. Schartl, M., Dougherty, C., Rutsch, W., Schmutzler, H. Am. Heart J. (1985) [Pubmed]
  14. Haemodynamic effects of molsidomine in patients with severe chronic coronary disease. Crexells, C., Lidón, R.M., Augé, J.M., Bosch, X., Pina, C., Garcia, J., Oriol, A. Eur. Heart J. (1985) [Pubmed]
  15. Comparison of anti-platelet properties of molsidomine, isosorbide-5-mononitrate and placebo in healthy volunteers. Drummer, C., Valta-Seufzer, U., Karrenbrock, B., Heim, J.M., Gerzer, R. Eur. Heart J. (1991) [Pubmed]
  16. Acute and chronic effects of molsidomine on pulmonary artery pressure and work capacity in patients with coronary heart disease. Jansen, W., Eggeling, T., Meyer, L., Tauchert, M., Hilger, H.H. Eur. Heart J. (1987) [Pubmed]
  17. Comparative trial of local pharmacotherapy with L-arginine, r-hirudin, and molsidomine to reduce restenosis after balloon angioplasty of stenotic rabbit iliac arteries. Kalinowski, M., Alfke, H., Bergen, S., Klose, K.J., Barry, J.J., Wagner, H.J. Radiology. (2001) [Pubmed]
  18. The influence of molsidomine and its active metabolite SIN-1 on fibrinolysis and platelet aggregation. Basista, M., Grodzińska, L., Swies, J. Thromb. Haemost. (1985) [Pubmed]
  19. Molsidomine inhibits the chemoattractant-induced respiratory burst in human neutrophils via a no-independent mechanism. Ervens, J., Seifert, R. Biochem. Pharmacol. (1992) [Pubmed]
  20. Modulation of prostacyclin/thromboxane formation by molsidomine during platelet-endothelial cell interactions. Bordet, J.C., Lagarde, M. Biochem. Pharmacol. (1988) [Pubmed]
  21. An assessment of single doses of 8 mg sustained-release molsidomine using serial exercise tests. Ruano, J., Zueco, J., López, C., Colman, T., Arnau, C., Pajarón, A. Eur. Heart J. (1988) [Pubmed]
  22. Heme oxygenase-1 is a cGMP-inducible endothelial protein and mediates the cytoprotective action of nitric oxide. Polte, T., Abate, A., Dennery, P.A., Schröder, H. Arterioscler. Thromb. Vasc. Biol. (2000) [Pubmed]
  23. Alterations of beta-adrenoceptor mediated relaxations of atherosclerotic human coronary arteries. Berkenboom, G., Fontaine, J., Degre, S. Eur. Heart J. (1989) [Pubmed]
  24. Inotropic effects of endothelin-1: interaction with molsidomine and with BQ 610. Beyer, M.E., Slesak, G., Hövelborn, T., Kazmaier, S., Nerz, S., Hoffmeister, H.M. Hypertension (1999) [Pubmed]
  25. Heme oxygenase in the retina in diabetes. Cukiernik, M., Mukherjee, S., Downey, D., Chakabarti, S. Curr. Eye Res. (2003) [Pubmed]
  26. Protection against concanavalin A-induced hepatocyte apoptosis by molsidomine is time-dependent. Ding, J.W., Wang, K., Brems, J.J., Gamelli, R.L. J. Am. Coll. Surg. (2004) [Pubmed]
  27. Intrarenal administration of molsidomine, a molecule releasing nitric oxide, reduces renal ischemia-reperfusion injury in rats. Rodriguez-Peña, A., Garcia-Criado, F.J., Eleno, N., Arevalo, M., Lopez-Novoa, J.M. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. (2004) [Pubmed]
  28. Peroxynitrite alters the catalytic activity of rodent liver proteasome in vitro and in vivo. Osna, N.A., Haorah, J., Krutik, V.M., Donohue, T.M. Hepatology (2004) [Pubmed]
  29. Protective effect of exogenous nitric oxide on the renal function and inflammatory response in a model of ischemia-reperfusion. Garcia-Criado, F.J., Eleno, N., Santos-Benito, F., Valdunciel, J.J., Reverte, M., Lozano-Sánchez, F.S., Ludeña, M.D., Gomez-Alonso, A., López-Novoa, J.M. Transplantation (1998) [Pubmed]
WikiGenes - Universities